Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the

Fu-qiang Gao1, Richard H Swartz, Philip Scheltens

  • 1LC Campbell Cognitive Neurology Research Unit, Heart and Stroke Foundation Centre for Stroke Recovery, University of Toronto, Toronto, ON, Canada. fgao@sri.utoronto.ca

Abstract

Insights

Comparing white matter hyperintensities (WMH) scales for dementia diagnosis, this study found simpler scales better for subgroup separation, while complex scales and volumetry correlated more with cognitive function, especially executive function.

Area of Science:

  • Neuroimaging
  • Neurology
  • Radiology

Background:

  • White matter hyperintensities (WMH) quantification methods on MRI are inconsistent, limiting clinical application.
  • Standardized WMH assessment is crucial for understanding neurodegenerative diseases.

Purpose of the Study:

  • To compare the clinical utility of three WMH rating scales (Fazekas, ARWMC, Scheltens) and a volumetric method.
  • To evaluate the trade-offs between scale complexity and their ability to differentiate dementia subgroups and correlate with cognition.

Main Methods:

  • WMH were rated using Fazekas, ARWMC, and Scheltens scales and computationally segmented for volume in 108 Alzheimer's Disease (AD), 23 Mild Cognitive Impairment (MCI), and 34 normal control (NC) patients.
  • Correlations with cognitive domains controlled for age, education, and global/hippocampal atrophy.

Main Results:

  • High intra- and inter-rater reliability (ICC=0.88-0.97) for all rating scales.
  • WMH scores strongly correlated with volumes (r=0.78-0.90) and with each other (r=0.86-0.91).
  • Fazekas scale separated AD, MCI, and NC; ARWMC, Scheltens, and volumes correlated with cognition (β=-0.19 to -0.24).

Conclusions:

  • WMH scale complexity did not impact validation against volumes but affected cognitive correlation.
  • Simpler scales excelled at subgroup separation, while complex scales/quantification better predicted cognitive measures, particularly executive function.
  • The optimal WMH assessment method depends on the specific clinical or research application.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...